Quince Therapeutics (NASDAQ:QNCX) Earns Outperform Rating from Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note issued to investors on Monday, Marketbeat reports. The firm issued an outperform rating and a $10.00 target price on the stock.

Several other analysts have also recently commented on the stock. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.34 on Monday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock has a market cap of $58.96 million, a price-to-earnings ratio of -1.08 and a beta of 0.71. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The business has a fifty day moving average of $1.48 and a 200-day moving average of $1.44.

Quince Therapeutics (NASDAQ:QNCX) last released its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. As a group, analysts predict that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of QNCX. Anfield Capital Management LLC bought a new position in shares of Quince Therapeutics during the fourth quarter valued at approximately $50,000. Virtu Financial LLC bought a new stake in Quince Therapeutics during the fourth quarter worth approximately $55,000. Two Sigma Investments LP bought a new position in Quince Therapeutics during the fourth quarter valued at about $57,000. Northern Trust Corp lifted its holdings in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares during the last quarter. Finally, Scharf Investments LLC bought a new position in shares of Quince Therapeutics in the fourth quarter valued at $170,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.